On April 11, 2016 Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, reported that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016 (Press release, Endocyte, APR 11, 2016, View Source [SID:1234510659]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation materials will be available on Endocyte’s website following presentation at the conference.
Presentations are as follows:
Abstract #: 262
Title: Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models
When: Sunday, April 17, 1 p.m. – 5 p.m. EDT
Session Title: Combination Chemotherapy
Location: Halls G-J, Poster Section 15
Abstract #: 3035
Title: Development and characterization of CCK2R-targeted SMDCs and identification of GIST as a potential therapeutic indication
When: Tuesday, April 19, 8 a.m. – 12 p.m. EDT
Session Title: Novel Targets and Pathways
Location: Halls G-J, Poster Section 17
Abstract #: 3754
Title: Pre-clinical studies of a highly potent Folate receptor targeted DNA crosslinking agent
When: Tuesday, April 19, 1 p.m. – 5p.m. EDT
Session Title: Novel Antitumor DNA-Reactive Agents
Location: Halls G-J, Poster Section 16
Abstract #: 4735
Title: Designing Novel Warheads for Targeted Therapies: SAR and Efficient Strategies for Synthesis of Analogs of Tubulysin
When: Wednesday, April 20, 8 a.m. – 12 p.m. EDT
Session Title: HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents